Dell joins HIMSS Innovation Center

Dell is the latest company to sign on as an industry collaborator of the HIMSS Innovation Center, joining other major health IT organizations at the 30,000-square-foot testing and exhibition facility in Cleveland.

Dell will showcase its healthcare technology solutions with an interactive display that asks visitors "Is your organization future ready?" 

“We are excited to join the state-of-the-art HIMSS Innovation Center and gain a new opportunity to share our technology solutions to address big data, mobility, security and cloud with healthcare providers in a collaborative environment,” said John Mullen, vice president and general manager, large institution sales at Dell, in a release. “Dell’s flexible, scalable and secure solutions are accelerating innovation with our healthcare customers to enable better patient outcomes.”

The HIMSS Innovation Center opened two years ago next to the Global Center for Health Innovation. The center serves as a showcase for health IT solutions that can integrate together and operate in concert with other emerging technologies to enable better care.

"Creative thinking is what happens in the Global Center and Dell adds distinctive value with its technology solutions to help the healthcare industry be more efficient and effective in delivering better patient outcomes,” Fred DeGrandis, managing director and chief administrative officer of the Global Center for Health Innovation.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.